|
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
Vancouver, BC--(Marketwire) - Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel...
|
|
|
India needs to allow phase I trials of new drugs developed abroad: Dr Nadig
Indian regulatory authorities should allow to conduct phase 1 study for compounds developed abroad if its expertise and skill to invent new drugs is to be recognized internationally according to Dr Ramanand Nadig, president and deputy...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel...
|
|
|
Oncolytics Biotech completes enrollment in head and neck cancer trial
(Datamonitor via COMTEX) -- ONCY | Quote | Chart | News | PowerRating -- Oncolytics Biotech, a Canadian biopharmaceutical company, has completed patient enrollment in the Phase II component of a Phase I/II UK trial of...
|
|
|
Phase Forward signs new deal with GSK
Data management specialist Phase Forward has landed a multi-million dollar clinical trial services contract with GSK.Under yesterdays agreement, Phase Forward will provide GlaxoSmithKline (GSK) with licensing and...
|
|
|
Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
- Completion of Phase I Paves Way for Expanding Bavituximab Cancer Program - - Inclusion of Patients with Diverse Advanced Cancers Along with Promising Interim Phase II Data Suggest Bavituximab Could Have Broad Anti-Cancer...
|
|
|
Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
- Completion of Phase I Paves Way for Expanding Bavituximab Cancer Program - - Inclusion of Patients with Diverse Advanced Cancers Along with Promising Interim Phase II Data Suggest Bavituximab Could Have Broad Anti-Cancer...
|
|
|
Phase Forward Customer GlaxoSmithKline Signs Multi-Year Agreements
- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that GlaxoSmithKline (GSK) has signed multi-year, multi-million dollar contracts covering...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY , July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.(TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN...
|
|
|
GlaxoSmithKline signs contract for Phase Forward clinical trials software
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, has announced that GlaxoSmithKline (GSK) has signed multi-year, multi-million dollar contracts covering...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
-(T-Net)--Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
- Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
VANCOUVER, BRITISH COLUMBIA, Jul 02 (MARKET WIRE) -- Tekmira Pharmaceuticals Corporation (TSX: TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
Tekmira Pharmaceuticals Corporation (TSX: TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 07/02/09 -- Tekmira Pharmaceuticals Corporation (TSX: TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
- Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
(Marketwire via COMTEX) -- TKMRF | Quote | Chart | News | PowerRating -- Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP,...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
VANCOUVER (Marketwire) - Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
- Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
- Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
Tekmira Pharmaceuticals Corporation (TSX:TKM - News) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
- Tekmira Pharmaceuticals Corporation (TSX: TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a...
|
|
|
Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
Tekmira Pharmaceuticals Corporation (TSX: TKM) announced today that it has initiated a Phase 1 human clinical trial for ApoB SNALP.ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R)
Oncolytics Biotech(R) Inc.Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY...
|
